By Mrinalika Roy and Mariam Sunny
Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
The trillion-dollar company also posted better-than-expected quarterly results and raised its full-year revenue forecast, and its shares jumped over 5% in early trading.
The strong results are likely to reassure investors that demand for Lilly's GLP-1 treatments remains resilient despite pricing pressure and intensifying competition from Novo, which launched an oral version of its Wegovy weight-loss drug in the U.S. earlier this year.
Sales of diabetes drug Mounjaro rose 91% to $9.94 billion, beating ****** ysts' estimates, while obesity drug Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion. The two drugs accounted for 64.7% of Lilly's revenue in the latest reported quarter.
#sales #novo #drugs
Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
The trillion-dollar company also posted better-than-expected quarterly results and raised its full-year revenue forecast, and its shares jumped over 5% in early trading.
The strong results are likely to reassure investors that demand for Lilly's GLP-1 treatments remains resilient despite pricing pressure and intensifying competition from Novo, which launched an oral version of its Wegovy weight-loss drug in the U.S. earlier this year.
Sales of diabetes drug Mounjaro rose 91% to $9.94 billion, beating ****** ysts' estimates, while obesity drug Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion. The two drugs accounted for 64.7% of Lilly's revenue in the latest reported quarter.
#sales #novo #drugs
15 days ago
